"Note they still haven't confirmed the primary endpoint for BOM2."

January 12, 2021: "Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure"

https://www.resverlogix.com/investors/news?article=688

“The unprecedented reduction in heart failure seen in BETonMACE further demonstrates the broad benefit these patients receive from apabetalone treatment,” said Donald McCaffrey, President and CEO of Resverlogix. “In agreement with the US Food and Drug Administration (FDA) – following receipt of the Company’s Breakthrough Therapy Designation announced on February 3, 2020, we will be including HHF in the composite primary endpoint for our upcoming registration-enabling study, BETonMACE2.”

Koo